Panhematin

— THERAPEUTIC CATEGORIES —
  • Inborn errors of metabolism

Panhematin Generic Name & Formulations

General Description

Hemin 350mg; per vial; pwd for IV infusion (7mg of hematin/mL after reconstitution); contains sodium carbonate 240mg, sorbitol 335mg; preservative-free.

Pharmacological Class

Delta-aminolevulinic acid synthetase inhibitor.

How Supplied

Single-dose vial—1

Panhematin Indications

Indications

Amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.

Limitations of Use

Intended to prevent an attack from reaching the critical stage of neuronal degeneration. Not effective in repairing neuronal damage.

Panhematin Dosage and Administration

Adult

Consider carbohydrate loading (eg, 400g glucose/day for 1–2 days) before initiation. If improvement unsatisfactory, give 1–4mg/kg/day of hematin via IV infusion over at least 30mins for 3–14 days. In more severe cases, this dose may be repeated no earlier than every 12hrs. Max 6mg/kg of hematin per 24hrs.

Children

<16yrs: not established.

Panhematin Contraindications

Not Applicable

Panhematin Boxed Warnings

Not Applicable

Panhematin Warnings/Precautions

Warnings/Precautions

Administer into large arm vein or a central venous catheter to avoid phlebitis. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jacob disease agent). Monitor iron and serum ferritin in multiple administrations. Latex allergy. Pregnancy (avoid in severe pre-eclampsia). Nursing mothers.

Panhematin Pharmacokinetics

See Literature

Panhematin Interactions

Interactions

Avoid CYP-inducing drugs that increase the activity of δ-aminolevulinic acid synthetase (eg, estrogens, barbituric acid derivatives, steroid metabolites). Avoid concomitant anticoagulants.

Panhematin Adverse Reactions

Adverse Reactions

Headache, pyrexia, infusion site reactions, phlebitis.

Panhematin Clinical Trials

See Literature

Panhematin Note

Not Applicable

Panhematin Patient Counseling

See Literature